Expression Of IL-22 And IL-6 In Serum Of Patients With Remission Of Chronic Obstructive Pulmonary Disease

Objective :To detect the levels of IL-22 and IL-6 in the peripheral blood of patients with remission of chronic obstructive pulmonary disease with different severity of pulmonary function and explore the relationship between IL-22, IL-6 and the occurrence and development of disease and the severity of pulmonary functionMethods: Experience group: a total of 82 patients with remission of chronic obstructive pulmonary disease in the second affiliated hospital of Kunming Medical University from January 2016 to February 2017 were selected (Patients with COPD who were admitted to hospital for acute exacerbation after 7-10 days of treatment),Based on forced expiratory volume in the first second by Pulmonary function test,these patients divided into four groups,including mild COPD group(Cgroup) (n=17),moderate COPD group (D group) (n=22), severe COPD group (E group ) (n=21 ),very severe COPD group (F group) (n=22), All patients was consistent with COPD global initiativefor (GOLD) the 2016 edition of the diagnosis and classification standard.control group : a total of 27 patients of health examination in January 2016 to Februrary 2017 in the Second Affiliated Hospital of Kunming Medical University Medical examination center, exclusion of Respiratory diseases and other related diseases, The patients were divided into control non-smoking groups (A group)(n=14) and control smoking group (B group) (n =13)?Clinical datas were collected including age,sex, body mass index, smoking index, pulmonary function index(FEV1, FEV1/Pred%) and serum IL-22, IL-6 levels.Results: 1. The difference of smoking index in COPD group and control smoking group, was not statistically significant (P=0.905), in the the control smoking group, mild COPD group, moderate COPD and severe COPD group, very severe COPD group, smoking index in five groups were not statistically significant (P both >0.05).2. FEV1/Pred (%), FEV1 in the COPD group (50.02±24.02%. 1.02±0.42L) was significantly lower than that of the control non-smoking group (98.57±2.03%?2.91±0.47L) and the control smoking group (95.92±5.22%?2.71±0.36L), the differences were both statistically significant (P both=0.000).The difference of control non-smoking group and controll smoking group had no statistical significance (P >0.05).3. IL-22, IL-6 levels in the COPD group (58.17±15.57ng/ml,109.81 ±52.77ng/ml)was significantly higher than that in control non-smoking group (41.28 ±12.33ng/ml,31.11±15.22ng/ml)and control smoking group(38.37±13.59ng/ml,29.83 ±14.77ng/ml),the differences were statistically significant (P both=0.000); control non-smoking group and control smoking group showed no significant significance (P> 0.05).IL-22,IL-6 in mild COPD group (53.42 ±14.98ng/ml, 96.09 ±38.62ng/ml), moderate COPD group(56.39±15.36ng/ml,105.77±56.25ng/ml),severe COPDgroup(59.02 ±17.58ng/ml,113.88 ±47.80 ng/ml), very severe COPD group (62.79±13.74 ng/ml, 120.56±62.89 ng/ml) were significantly higher than those of control non-smoking group(38.37±13.59ng/ml, 29.83±14.77ng/ml)and control smoking group(41.28±12.33ng/ml,31.11±15.22ng/ml), the differences were statistically significant (Pboth=0.000); there was no significant difference (P > 0.05) in the mild COPD group, moderate COPD group, severe COPD group and very severe COPD group .4. IL-22 and lung function index (FEV1) were negatively correlated (R=-0.532,P=0.000), FEV1 decreased with the elevated levels of IL-22; IL-6 and lung function index (FEV1) were negatively correlated (R=-0675, P=0.000), FEV1 decreased with the elevated level of IL-6.Conclusions:1.Combined detection of cytokines in the serum of patients has a certain significance to study the pathogenesis of COPD.2.IL-6 and IL-22 were involved in the airway inflammation in COPD, and expression level of IL-22 and IL-6 negatively correlated with FEV1.3. In the early stage of remission of chronic obstructive pulmonary disease, there may be a change in the expression of IL-22 and IL-6 and showed low sustained systemic inflammatory reaction may occur at the stage of remission of chronic obstructive pulmonary disease.